Clinical Trials

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT01336634 2022-04-04

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

177 enrolled 19 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02083354 2022-02-01

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

77 enrolled 43 charts

Melanoma, Neoplasms, Skin Neoplasms

NCT01677741 2021-11-24

A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

Phase 1/2 Completed

85 enrolled 25 charts

CNS

Brain Neoplasms

NCT02110355 2021-03-26

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

31 enrolled

Melanoma, Neoplasms

NCT01584648 2021-02-17

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Phase 3 Completed

423 enrolled 15 charts

Melanoma

NCT03352947 2020-12-08

INTERIM

79 enrolled

Melanoma

NCT01682213 2020-05-26

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

23 enrolled 10 charts

Melanoma

NCT01072175 2019-07-05

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

430 enrolled 61 charts

Melanoma, Neoplasms

NCT02039947 2019-05-21

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

127 enrolled 17 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02027961 2019-05-17

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

68 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma, Neoplasm Metastasis

NCT01231594 2019-03-22

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

214 enrolled

Neoplasms

NCT02142036 2019-03-13

MetAction

50 enrolled

Neoplasm Metastasis

NCT01713972 2019-03-01

Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors

23 enrolled

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT02296996 2019-01-23

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

25 enrolled

Melanoma

NCT01767454 2017-11-14

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

38 enrolled

Melanoma

NCT00880321 2017-11-13

A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors

170 enrolled

Neoplasms

NCT01262963 2017-11-13

An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors

4 enrolled

Neoplasms

NCT01340833 2017-11-13

Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

6 enrolled

Neoplasms

NCT01340846 2017-11-13

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

48 enrolled

Neoplasms

NCT01582997 2017-11-13

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors

12 enrolled

Neoplasms

NCT01738451 2017-11-13

A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors

50 enrolled

Neoplasms

NCT01227889 2017-10-04

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Phase 3 Completed

251 enrolled 21 charts

Melanoma, Neoplasms

NCT01153763 2017-09-27

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma

92 enrolled 22 charts

Melanoma

NCT01928940 2017-07-24

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

12 enrolled 28 charts

Melanoma

NCT02082665 2017-07-24

Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

6 enrolled

Melanoma, Neoplasms

NCT01534897 2017-03-15

Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436

Phase NA Completed

10 enrolled 9 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Neoplasm Metastasis, Thyroid Neoplasms

NCT01619774 2016-12-12

An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor

28 enrolled 7 charts